Latest News

Appeals judges: Chicago not right court for John Crane's asbestos fraud RICO claims vs Simon Greenstone, Shein Law

By Jonathan Bilyk | Jun 4, 2018

A federal appeals panel in Chicago has agreed industrial seals and couplings maker John Crane Inc. should be afforded the chance to air its claims two law firms allegedly engaged in racketeering and fraud in the way they pressed asbestos-related personal injury claims against the company in the past. However, the judges also agreed with lower court judges that Chicago federal court is not the right place for John Crane can pursue its claims.

Trial lawyer panel: Plaintiffs' lawyers adapting strategies to fit post-BristolMyersSquibb legal landscape

By Jonathan Bilyk | May 30, 2018

While the U.S. Supreme Court's Bristol Myers Squibb ruling has resulted in some big wins for businesses targeted by the plaintiffs' bar, new strategies and theories deployed by plaintiffs' lawyers may be blunting the further impact of that decision, despite high hopes from some it would largely thwart the ability of out-of-state plaintiffs to sue out-of-state defendants in a favorable court forum.

Verdict much lower, but AbbVie wants $3.2M award tossed in second testosterone class action test trial

By Dan Churney | Apr 30, 2018

North Chicago-based drugmaker AbbVie is resisting what it is calling a jury's “confused and inconsistent” $3.2 million verdict, after the company lost a second trial in Chicago federal court – one in which it was ordered to pay $147 million less than the first trial – over a man’s claims AbbVie allegedly failed to warn its product AndroGel could bring on a heart attack.

Report: Asbestos litigation declines nationwide, slightly in Cook Co., still pervasive in three IL counties

By Jonathan Bilyk and Ann Maher | Mar 23, 2018

As the number of new asbestos lawsuits declined nationally, activity in Illinois’ three hotbeds for asbestos litigation showed few signs of ebbing in 2017, even though the distribution of filing activity has shifted slightly.

From Legal Newsline

Plaintiff lawyers see nationwide settlement as only end for opioid lawsuits

By Daniel Fisher | Mar 7, 2018

SAN FRANCISCO (Legal Newsline) - Plaintiff lawyers meeting in San Francisco last week for a conference on opioid litigation acknowledged that the hundreds of lawsuits they have filed in state and federal court will be difficult to resolve without an unprecedented national settlement whose mechanics are still difficult to predict.

Black workers OK to continue discrimination suit vs staffer, employers allegedly favoring Hispanics

By DM Herra | Mar 7, 2018

A group of companies facing racial discrimination lawsuits for allegedly passing over black workers in favor of Hispanic workers when hiring temporary workers, failed in their attempt to have the complaints dismissed.

Bud's Ambulance allegedly scanned employee fingerprints without consent

By Louie Torres | Mar 2, 2018

An employee has filed a class-action lawsuit against Bud's Ambulance for allegedly violating state law.

IL appeals court upholds dismissal of class action challenging Chicago red light camera program law

By Jonathan Bilyk | Feb 14, 2018

Saying state law designates Chicago’s red light and speed camera enforcement programs as something different from ordinary traffic laws, a state appeals court has again handed a defeat to a class action attempting to overthrow the city’s automated traffic citation program, which annually adds millions of dollars in fines from ticketed motorists to the city’s coffers.

From Legal Newsline

Opioid judge doesn't want media to know details of settlement talks

By Daniel Fisher | Feb 9, 2018

CLEVELAND (Legal Newsline) - The judge overseeing multidistrict litigation against opioid manufacturers and distributors has named the teams of lawyers who will try to negotiate a settlement of hundreds of federal lawsuits - a complex task given parallel investigations and litigation by state attorneys general and potentially conflicting goals of private attorneys and their government counterparts.

Jury declares Abbvie's Androgel didn't cause man's lung clots, Abbvie didn't falsely market medication

By Jonathan Bilyk | Jan 26, 2018

After split verdicts in two prior trials over alleged harmful side effects and alleged misleading marketing of its testosterone replacement drug led to questionable verdicts worth more than $140 million each, drugmaker Abbvie has scored a clean win in the latest jury review of a plaintiff’s claims over the promotion and health impacts of Androgel.

From Legal Newsline

Usual Suspects: Lawyers used to getting their way in MDL process to lead opioid litigation

By Daniel Fisher | Jan 24, 2018

CLEVELAND (Legal Newsline) - There will be a lot of familiar faces in U.S. District Judge Dan Polster’s courtroom in Cleveland on Jan. 31, when lawyers gather for a hearing on multidistrict litigation against the nation’s opioid manufacturers and distributors.

From Madison County Record

Illinois Supreme Court mulling who gets consolidated opioid cases – Cook Co. or Springfield judge

By Record News | Jan 23, 2018

SPRINGFIELD – Supreme Court Justices must decide whether suits that counties continue filing against opioid manufacturers belong with a judge from Cook County or a judge from Springfield.

Contract: Simmons, Meyers firms to split 25 percent cut of Cook County's take from any opioid lawsuit payment

By Jonathan Bilyk | Jan 12, 2018

Lawyers hired by Cook County to help press the county’s case against drug companies over the proliferation of opioid painkillers stand to pocket at least a quarter of Cook County’s cut of any settlement or dollar amount awarded by a court.

Appeals panel: Chance exists Ledcor might be held liable for other firm's worker, so insurer must defend

By David Hutton | Jan 7, 2018

Noting there is a possibility contractor Ledcor could yet be ordered to pay for injuries suffered on a job site by another company's employee, a state appeals panel has refused to let Pekin Insurance walk away from the case.

Insurer can treat thousands of asbestos claims vs manufacturer as single insurable occurrence, appeals court says

By Dee Thompson | Jan 5, 2018

A state appeals panel has come down on the side of insurers in an ongoing legal dispute with a manufacturer over the question of whether thousands of asbestos exposure-related lawsuits arising from the same company's products should be treated as a single "occurrence" or multiple occurrences for the purposes of determining how much the insurer would be obligated to pay.

Judge: Suit can proceed vs Target claiming justifies firing Hispanics over fake Social Security numbers

By David Hutton | Dec 29, 2017

A federal judge will allow a woman to proceed, for now, with a lawsuit against Target, claiming the retailer targeted her and other Hispanic employees by accusing them of having fake Social Security numbers.

Drugmaker Auxilium wins at jury in its first bellwether trial over testosterone therapy drug Testim

By Jonathan Bilyk | Nov 16, 2017

While their competitor AbbVie seeks to undo jury verdicts worth nearly $290 million over testosterone replacement therapy drugs, drugmaker Auxilium has received a clean bill from a jury in its first court test over claims it and other similar drugmakers should be made to pay for alleged misleading marketing that led men to take the drugs, and suffered heart attacks as a result.

Attorney says 'no chance' that $140 million punitive damages judgment against AbbVie will stand

By Elizabeth Alt | Nov 9, 2017

North Chicago-based drugmaker AbbVie has asked a federal judge to toss out a $140 million verdict against it for allegedly mismarketing its testosterone replacement therapy drug, Androgel. And in the view of a Chicago attorney whose practice focuses on Supreme Court and appellate cases, as well as class actions, there is "no chance" that judgment will be allowed to stand.

Drug maker AbbVie wants to slip from $140M verdict, says jury ignored evidence

By Dan Churney | Nov 6, 2017

North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA.

Judge: Testosterone replacement drug bellwether OK to proceed vs Testim maker Auxilium

By Jonathan Bilyk | Oct 24, 2017

After two federal juries delivered $140 million verdicts against AbbVie, competing drugmaker Auxilium will be headed to trial over claims its testosterone replacement therapy drug Testim caused heart attacks in men who took the drug to treat “off-label” conditions, spurred by what plaintiffs alleged was misleading marketing from drugmakers.

The Record Network